The purpose of this program continues to be to support the training of pre- and post-doctoral fellows in several biomedical aspects of drugs of abuse. The principal focus of the program is interdisciplinary mentoring by the faculty in the Departments of Pharmacology and Microbiology and Immunology. The training will focus on the interrelationships among drugs of abuse and endogenous substances such as neuropeptide and cytokines. In addition to their classical effects, the drugs will be studied for their actions on the immune system and various aspects of behavior, including the mechanisms responsible for the effects. Members of participating departments will bring their expertise and specialized techniques to the program. Members of other departments will bring their expertise and specialized techniques to the program. Members of other departments will bring their expertise and specialized techniques to the program. Members of other departments also contribute in areas such as behavior, signal transduction, second messenger receptor systems, neural mechanisms, and genetics. Current research by members of our program involves opioids, alcohol cannabinoids, and cocaine, as well as opioid and other rain neuropeptides. Techniques include in vitro and in vivo approaches and methods that range from molecular to behavioral. For acceptance into the program, predoctoral trainees will have completed at least 1 year of graduate training. They will be exposed to a rigorous program for both didactic and laboratory experiences, with the aim of producing independent researchers highly knowledgeable and expert in the broad field of drugs of abuse. Postdoctoral trainees with the Ph.D. degree will have received their doctorate or defended their thesis as part of a well-recognized graduate program prior to beginning training in this program; trainees with the M.D. degree will have completed at least 1 year of residency. Postdoctoral trainees will concentrate on research during their training but will be required to audit or take courses related to the field of drug abuse, should their background indicate that such courses are desirable. All trainees will receive instruction in pharmacology, immunology, and behavior. In addition, all trainees will receive instruction in teaching, presentation of data at meetings and seminars, preparation and evaluation of manuscripts and preparation of grants. We expect them to become careful, independent, and productive researchers in the drug abuse field and/or the related fields of neuropeptides and neuroimmunology. The primary facilities in this program will be in the Departments of Pharmacology and Microbiology and Immunology at the Temple University School of Medicine. We are requesting funds to continue and expand on the accomplishments of the first 9 years of this program.

Agency
National Institute of Health (NIH)
Institute
National Institute on Drug Abuse (NIDA)
Type
Institutional National Research Service Award (T32)
Project #
5T32DA007237-12
Application #
6174649
Study Section
Special Emphasis Panel (ZDA1-MXS-M (12))
Program Officer
Babecki, Beth
Project Start
1988-09-01
Project End
2004-06-30
Budget Start
2000-07-15
Budget End
2001-06-30
Support Year
12
Fiscal Year
2000
Total Cost
$297,583
Indirect Cost
Name
Temple University
Department
Pharmacology
Type
Schools of Medicine
DUNS #
City
Philadelphia
State
PA
Country
United States
Zip Code
19122
Ward, Sara Jane; Castelli, Francesca; Reichenbach, Zachary W et al. (2018) Surprising outcomes in cannabinoid CB1/CB2 receptor double knockout mice in two models of ischemia. Life Sci 195:1-5
Oliver, Chicora F; Simmons, Steven J; Nayak, Sunil U et al. (2018) Chemokines and 'bath salts': CXCR4 receptor antagonist reduces rewarding and locomotor-stimulant effects of the designer cathinone MDPV in rats. Drug Alcohol Depend 186:75-79
Gentile, Taylor A; Simmons, Steven J; Barker, David J et al. (2018) Suvorexant, an orexin/hypocretin receptor antagonist, attenuates motivational and hedonic properties of cocaine. Addict Biol 23:247-255
Hicks, Callum; Huang, Peng; Ramos, Linnet et al. (2018) Dopamine D1-Like Receptor Agonist and D2-Like Receptor Antagonist (-)-Stepholidine Reduces Reinstatement of Drug-Seeking Behavior for 3,4-Methylenedioxypyrovalerone (MDPV) in Rats. ACS Chem Neurosci 9:1327-1337
Wickens, Megan M; Bangasser, Debra A; Briand, Lisa A (2018) Sex Differences in Psychiatric Disease: A Focus on the Glutamate System. Front Mol Neurosci 11:197
Andrews, Allison M; Lutton, Evan M; Cannella, Lee A et al. (2018) Characterization of human fetal brain endothelial cells reveals barrier properties suitable for in vitro modeling of the BBB with syngenic co-cultures. J Cereb Blood Flow Metab 38:888-903
Simmons, Steven J; Gregg, Ryan A; Tran, Fionya H et al. (2018) Comparing rewarding and reinforcing properties between 'bath salt' 3,4-methylenedioxypyrovalerone (MDPV) and cocaine using ultrasonic vocalizations in rats. Addict Biol 23:102-110
Hill, Jeremy D; Zuluaga-Ramirez, Viviana; Gajghate, Sachin et al. (2018) Activation of GPR55 increases neural stem cell proliferation and promotes early adult hippocampal neurogenesis. Br J Pharmacol :
Sagar, Divya; Singh, Narendra P; Ginwala, Rashida et al. (2017) Antibody blockade of CLEC12A delays EAE onset and attenuates disease severity by impairing myeloid cell CNS infiltration and restoring positive immunity. Sci Rep 7:2707
Merkel, Steven F; Andrews, Allison M; Lutton, Evan M et al. (2017) Dexamethasone Attenuates the Enhanced Rewarding Effects of Cocaine Following Experimental Traumatic Brain Injury. Cell Transplant 26:1178-1192

Showing the most recent 10 out of 200 publications